当前位置: 首页 >> 检索结果
41. Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study.
作者: Jim Christenson.;Michael D Hill.;Richard H Swartz.;Corey Adams.;Oscar Benavente.;Leanne K Casaubon.;Sheldon Cheskes.;Aravind Ganesh.;Jonathan Dave Garman.;Cameron Harris.;Devin R Harris.;Kathy Heard.;Sandra Jenneson.;Yatika Kohli.;Michelle Leroux.;Diana Mayor-Nunez.;George Medvedev.;Manu Mehdiratta.;Laurie J Morrison.;Johanna Maria Ospel.;Sarah Pennington.;Yael Perez.;Daniel Selchen.;Alexander Stebner.;John Tallon.;Aleksander Tkach.;Pieter Richard Verbeek.;Michael Tymianski.
来源: Lancet. 2025年405卷10478期571-582页
Nerinetide is a neuroprotectant effective in preclinical models of acute ischaemic stroke when administered within 3 h of onset. However, the clinical evaluation of neuroprotectants in this short timeframe is challenging. We sought to establish the feasibility, safety, and effectiveness of nerinetide when given before hospital arrival within 3 h of symptom onset of suspected stroke.
42. Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial.
作者: Michael D Hill.;Mayank Goyal.;Andrew M Demchuk.;Bijoy K Menon.;Thalia S Field.;William C Guest.;Jorg Berrouschot.;Albrecht Bormann.;Mirko Pham.;Karl G Haeusler.;Diedrick W J Dippel.;Pieter J van Doormaal.;Franziska Dorn.;Felix J Bode.;Brian A van Adel.;Demetrios J Sahlas.;Richard H Swartz.;Leodante Da Costa.;Johanna M Ospel.;Rosalie V McDonough.;Karla J Ryckborst.;Mohammed A Almekhlafi.;Kathy J Heard.;David J Garman.;Corey Adams.;Yatika Kohli.;Bridget A Schoon.;Brian H Buck.;Mario Muto.;Atif Zafar.;Hauke Schneider.;Jonathan A Grossberg.;Leonard L L Yeo.;Jason W Tarpley.;Marios-Nikos Psychogios.;Jonathan M Coutinho.;Nicola Limbucci.;Volker Puetz.;Michael E Kelly.;Bruce C V Campbell.;Sven Poli.;Alexandre Y Poppe.;Jai J Shankar.;Ronil Chandra.;Dar Dowlatshahi.;George A Lopez.;Luigi Cirillo.;Aimen Moussaddy.;Michael Devlin.;Pablo Garcia-Bermejo.;Jennifer L Mandzia.;Mona Skjelland.;Anne Hege Aamodt.;Frank L Silver.;Timothy J Kleinig.;Guglielmo Pero.;Jens Minnerup.;Ryan A McTaggart.;Ajit S Puri.;Albert H Y Chiu.;Gernot Reimann.;Gordon J Gubitz.;Marie-Christine Camden.;Seon Kyu Lee.;Eric Sauvageau.;Sibu Mundiyanapurath.;Donald F Frei.;Hana Choe.;Marcello Rocha.;Jan Gralla.;Peter Bailey.;Sebastian Fischer.;Thomas Liebig.;Konstantin Dimitriadis.;Dheeraj Gandhi.;René Chapot.;Albert Jin.;Ameer E Hassan.;Wim van Zwam.;Ilko L Maier.;Martin Wiesmann.;Wolf-Dirk Niesen.;Rajiv Advani.;Agnethe Eltoft.;Negar Asdaghi.;Cynthia Murphy.;Luca Remonda.;Darshan Ghia.;Olav Jansen.;Markus Holtmannspoetter.;Victoria Hellstern.;Karsten Witt.;Annette Fromme.;Shahid M Nimjee.;David Turkel-Parella.;Dominik Michalski.;Christian Maegerlein.;Carol Huilian Tham.;Michael Tymianski.; .
来源: Lancet. 2025年405卷10478期560-570页
In the ESCAPE-NA1 trial, treatment with nerinetide, an eicosapeptide that interferes with post-synaptic density protein 95, was associated with improved functional outcome among patients with acute ischaemic stroke due to large vessel occlusion undergoing endovascular thrombectomy without co-treatment with an intravenous thrombolytic agent. There was no benefit when intravenous thrombolytic agent co-treatment was used. We sought to confirm the clinical benefit of nerinetide in the absence of previous intravenous thrombolytic drug treatment.
43. Normobaric hyperoxia combined with endovascular treatment for acute ischaemic stroke in China (OPENS-2 trial): a multicentre, randomised, single-blind, sham-controlled trial.
作者: Weili Li.;Jing Lan.;Ming Wei.;Lan Liu.;Chengbei Hou.;Zhifeng Qi.;Chuanhui Li.;Liqun Jiao.;Qi Yang.;Wenhuo Chen.;Shuling Liu.;Xincan Yue.;Qinglin Dong.;Haicheng Yuan.;Zongen Gao.;Xiangbin Wu.;Changming Wen.;Tong Li.;Changchun Jiang.;Di Li.;Zuoquan Chen.;Junfeng Shi.;Wanchao Shi.;Jinglin Yuan.;Yijie Qin.;Binglong Li.;Marc Fisher.;Wuwei Feng.;Ke Jian Liu.;Xunming Ji.; .
来源: Lancet. 2025年405卷10477期486-497页
Endovascular treatment improves the recanalisation rate for patients with acute ischaemic stroke; however, even with endovascular treatment, approximately half of patients do not have a favourable functional outcome. We aimed to evaluate the effect of normobaric hyperoxia combined with endovascular treatment on functional outcomes up to 90 days after treatment in patients who had an acute ischaemic stroke with large-vessel occlusion.
44. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
作者: Nirosen Vijiaratnam.;Christine Girges.;Grace Auld.;Rachel McComish.;Alexa King.;Simon S Skene.;Steve Hibbert.;Alan Wong.;Sabina Melander.;Rachel Gibson.;Helen Matthews.;John Dickson.;Camille Carroll.;Abigail Patrick.;Jemma Inches.;Monty Silverdale.;Bethan Blackledge.;Jessica Whiston.;Michele Hu.;Jessica Welch.;Gordon Duncan.;Katie Power.;Sarah Gallen.;Jacqueline Kerr.;K Ray Chaudhuri.;Lucia Batzu.;Silvia Rota.;Edwin Jabbari.;Huw Morris.;Patricia Limousin.;Nigel Greig.;Yazhou Li.;Vincenzo Libri.;Sonia Gandhi.;Dilan Athauda.;Kashfia Chowdhury.;Tom Foltynie.
来源: Lancet. 2025年405卷10479期627-636页
GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk and progression of Parkinson's disease. We aimed to establish whether the GLP-1 receptor agonist, exenatide, could slow the rate of progression of Parkinson's disease.
45. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
作者: Janet A Dunn.;Peter Donnelly.;Nada Elbeltagi.;Andrea Marshall.;Amy Hopkins.;Alastair M Thompson.;Riccardo Audisio.;Sarah E Pinder.;David A Cameron.;Sue Hartup.;Lesley Turner.;Annie Young.;Helen Higgins.;Eila K Watson.;Sophie Gasson.;Peter J Barrett-Lee.;Claire Hulme.;Bethany Shinkins.;Peter S Hall.;Andrew Evans.
来源: Lancet. 2025年405卷10476期396-407页
The frequency of mammographic surveillance for women after diagnosis of breast cancer varies globally. The aim of this study was to evaluate whether less than annual mammography was non-inferior in terms of breast cancer-specific survival in women aged 50 years or older.
46. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
作者: Thierry André.;Elena Elez.;Heinz-Josef Lenz.;Lars Henrik Jensen.;Yann Touchefeu.;Eric Van Cutsem.;Rocio Garcia-Carbonero.;David Tougeron.;Guillermo Ariel Mendez.;Michael Schenker.;Christelle de la Fouchardiere.;Maria Luisa Limon.;Takayuki Yoshino.;Jin Li.;Jose Luis Manzano Mozo.;Laetitia Dahan.;Giampaolo Tortora.;Myriam Chalabi.;Eray Goekkurt.;Maria Ignez Braghiroli.;Rohit Joshi.;Timucin Cil.;Francine Aubin.;Elvis Cela.;Tian Chen.;Ming Lei.;Lixian Jin.;Steven I Blum.;Sara Lonardi.
来源: Lancet. 2025年405卷10476期383-395页
CheckMate 8HW prespecified dual primary endpoints, assessed in patients with centrally confirmed microsatellite instability-high or mismatch repair-deficient status: progression-free survival with nivolumab plus ipilimumab compared with chemotherapy as first-line therapy and progression-free survival with nivolumab plus ipilimumab compared with nivolumab alone, regardless of previous systemic treatment for metastatic disease. In our previous report, nivolumab plus ipilimumab showed superior progression-free survival versus chemotherapy in first-line microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the CheckMate 8HW trial. Here, we report results from the prespecified interim analysis for the other primary endpoint of progression-free survival for nivolumab plus ipilimumab versus nivolumab across all treatment lines.
47. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
作者: Michelle C Williams.;Ryan Wereski.;Christopher Tuck.;Philip D Adamson.;Anoop S V Shah.;Edwin J R van Beek.;Giles Roditi.;Colin Berry.;Nicholas Boon.;Marcus Flather.;Steff Lewis.;John Norrie.;Adam D Timmis.;Nicholas L Mills.;Marc R Dweck.;David E Newby.; .
来源: Lancet. 2025年405卷10475期329-337页
The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in management and outcomes.
48. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
作者: Nisha R Acharya.;Athimalaipet V Ramanan.;Alison B Coyne.;Kathryn L Dudum.;Elia M Rubio.;Sydney M Woods.;Catherine M Guly.;Elena Moraitis.;Harry J D Petrushkin.;Kate Armon.;Narman Puvanachandra.;Jessy T Choi.;Daniel P Hawley.;Benjamin F Arnold.; .
来源: Lancet. 2025年405卷10475期303-313页
Adalimumab is an effective treatment for juvenile idiopathic arthritis-associated uveitis. Data are scarce on the effects of discontinuing adalimumab after control of the disease had been reached. We aimed to assess efficacy and safety of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis.
49. Appendicectomy versus antibiotics for acute uncomplicated appendicitis in children: an open-label, international, multicentre, randomised, non-inferiority trial.
作者: Shawn D St Peter.;Janelle R Noel-MacDonnell.;Nigel J Hall.;Simon Eaton.;Janne S Suominen.;Tomas Wester.;Jan F Svensson.;Markus Almström.;E Pete Muenks.;Marianne Beaudin.;Nelson Piché.;Mary Brindle.;Ali MacRobie.;Richard Keijzer.;Helene Engstrand Lilja.;Ann-Marie Kassa.;Tim Jancelewicz.;Andreana Butter.;Jacob Davidson.;Erik Skarsgard.;Yap Te-Lu.;Shireen Nah.;Andrew R Willan.;Agostino Pierro.
来源: Lancet. 2025年405卷10474期233-240页
Support for the treatment of uncomplicated appendicitis with non-operative management rather than surgery has been increasing in the literature. We aimed to investigate whether treatment of uncomplicated appendicitis with antibiotics in children is inferior to appendicectomy by comparing failure rates for the two treatments.
50. Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
作者: David Fiorentino.;Aaron R Mangold.;Victoria P Werth.;Lisa Christopher-Stine.;Alisa Femia.;Myron Chu.;Amy C M Musiek.;Jason C Sluzevich.;Lauren V Graham.;Anthony P Fernandez.;Rohit Aggarwal.;Kerri Rieger.;Karen M Page.;Xingpeng Li.;Craig Hyde.;Natalie Rath.;Abigail Sloan.;Barry Oemar.;Anindita Banerjee.;Mikhail Salganik.;Christopher Banfield.;Srividya Neelakantan.;Jean S Beebe.;Michael S Vincent.;Elena Peeva.;Ruth Ann Vleugels.
来源: Lancet. 2025年405卷10473期137-146页
Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
51. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
作者: Bruno Sangro.;Masatoshi Kudo.;Joseph P Erinjeri.;Shukui Qin.;Zhenggang Ren.;Stephen L Chan.;Yasuaki Arai.;Jeong Heo.;Anh Mai.;Jose Escobar.;Yamil Alonso Lopez Chuken.;Jung-Hwan Yoon.;Won Young Tak.;Valeriy V Breder.;Tanita Suttichaimongkol.;Mohamed Bouattour.;Shi-Ming Lin.;Jean-Marie Peron.;Quang T Nguyen.;Lunan Yan.;Chang-Fang Chiu.;Florinda A Santos.;Anil Veluvolu.;Satheesh Chiradoni Thungappa.;Marco Matos.;Magdalena Żotkiewicz.;Stephanie I Udoye.;John F Kurland.;Gordon J Cohen.;Riccardo Lencioni.; .
来源: Lancet. 2025年405卷10474期216-232页
Transarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-free survival is still approximately 7 months. We aimed to assess whether adding durvalumab, with or without bevacizumab, might improve progression-free survival.
52. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
作者: Masatoshi Kudo.;Zhenggang Ren.;Yabing Guo.;Guohong Han.;Hailan Lin.;Jinfang Zheng.;Sadahisa Ogasawara.;Ji Hoon Kim.;Haitao Zhao.;Chuan Li.;David C Madoff.;R Mark Ghobrial.;Tomokazu Kawaoka.;René Gerolami.;Masafumi Ikeda.;Hiromitsu Kumada.;Anthony B El-Khoueiry.;Arndt Vogel.;Xiang Peng.;Kalgi Mody.;Corina Dutcus.;Leonid Dubrovsky.;Abby B Siegel.;Richard S Finn.;Josep M Llovet.; .
来源: Lancet. 2025年405卷10474期203-215页
Transarterial chemoembolisation (TACE) is standard care for unresectable, non-metastatic hepatocellular carcinoma. We aimed to evaluate the addition of lenvatinib and pembrolizumab to TACE versus dual placebo plus TACE in patients with unresectable, non-metastatic hepatocellular carcinoma.
53. Effect of a spatial repellent on malaria incidence in an area of western Kenya characterised by high malaria transmission, insecticide resistance, and universal coverage of insecticide treated nets (part of the AEGIS Consortium): a cluster-randomised, controlled trial.
作者: Eric O Ochomo.;John E Gimnig.;Quentin Awori.;Bernard Abong'o.;Prisca Oria.;Nickline K Ashitiba.;Brian Polo.;Vincent Moshi.;Hilda Otanga.;Ferdinard Adung'o.;Eunice A Ouma.;Susan Outa.;Edith Ramaita.;Rebecca Levine.;Wycliffe Odongo.;Steven A Harvey.;April Monroe.;Ashley Hudson.;Bradley Sandberg.;Jared Hendrickson.;Xingyuan Zhao.;Ruyu Zhou.;Fang Liu.;Nicole L Achee.;John P Grieco.
来源: Lancet. 2025年405卷10473期147-156页
Spatial repellent products are used for prevention of insect bites, and a body of evidence exists on spatial repellent entomological efficacy. A new option for vector control, spatial repellent products are designed to release active ingredient into the air for disruption of human-vector contact thereby reducing human exposure to mosquito-borne pathogens. Clinical trials have shown spatial repellent epidemiological efficacy against Aedes-borne viruses but inconclusive outcomes against malaria. We aimed to show and quantify the protective efficacy of spatial repellents in reducing malaria infection incidence in Busia County, Kenya.
54. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
作者: David T Rubin.;Jessica R Allegretti.;Julián Panés.;Nicole Shipitofsky.;Shadi S Yarandi.;Kuan-Hsiang Gary Huang.;Matthew Germinaro.;Rebbecca Wilson.;Hongyan Zhang.;Jewel Johanns.;Brian G Feagan.;Tadakazu Hisamatsu.;Gary R Lichtenstein.;Brian Bressler.;Laurent Peyrin-Biroulet.;Bruce E Sands.;Axel Dignass.; .
来源: Lancet. 2025年405卷10472期33-49页
Interleukin-23 inhibition is effective in treating ulcerative colitis. Guselkumab is a dual-acting, human IgG1, interleukin-23p19 subunit inhibitor that potently neutralises interleukin-23 and can bind to CD64. We aimed to evaluate the efficacy and safety of guselkumab as induction and maintenance therapy in patients with ulcerative colitis.
55. TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial.
作者: Elvin Kedhi.;Renicus S Hermanides.;Jan-Henk E Dambrink.;Sandeep K Singh.;Jurriën M Ten Berg.;DirkJan van Ginkel.;Martin Hudec.;Giovanni Amoroso.;Ignacio J Amat-Santos.;Martin Andreas.;Rui Campante Teles.;Guillaume Bonnet.;Eric Van Belle.;Lenard Conradi.;Leen van Garsse.;Wojtek Wojakowski.;Vassilis Voudris.;Jerzy Sacha.;Pavel Cervinka.;Erik Lipsic.;Samer Somi.;Luis Nombela-Franco.;Sonja Postma.;Kerstin Piayda.;Giuseppe De Luca.;Evelien Kolkman.;Krzysztof P Malinowski.;Thomas Modine.; .
来源: Lancet. 2025年404卷10471期2593-2602页
Patients with severe aortic stenosis present frequently (∼50%) with concomitant obstructive coronary artery disease. Current guidelines recommend combined surgical aortic valve replacement (SAVR) and coronary artery bypass grafting (CABG) as the preferred treatment. Transcatheter aortic valve implantation (TAVI) and fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) represent a valid treatment alternative. We aimed to test the non-inferiority of FFR-guided PCI plus TAVI versus SAVR plus CABG in patients with severe aortic stenosis and complex coronary artery disease.
56. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
作者: Marc Ferrante.;Geert D'Haens.;Vipul Jairath.;Silvio Danese.;Minhu Chen.;Subrata Ghosh.;Tadakazu Hisamatsu.;Jaroslaw Kierkus.;Britta Siegmund.;Sonja Michelle Bragg.;Wallace Crandall.;Frederick Durand.;Emily Hon.;Zhantao Lin.;Michelle Ugolini Lopes.;Nathan Morris.;Marijana Protic.;Hilde Carlier.;Bruce E Sands.; .
来源: Lancet. 2024年404卷10470期2423-2436页
Mirikizumab, a humanised monoclonal antibody that inhibits IL-23p19, is effective in moderate-to-severe ulcerative colitis. We aimed to evaluate the efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease.
57. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
作者: Alberto Bossi.;Stéphanie Foulon.;Xavier Maldonado.;Paul Sargos.;Ray MacDermott.;Paul Kelly.;Aude Fléchon.;Bertrand Tombal.;Stephane Supiot.;Dominik Berthold.;Philippe Ronchin.;Gabriel Kacso.;Naji Salem.;Fabio Calabro.;Jean-François Berdah.;Ali Hasbini.;Marlon Silva.;Jihane Boustani.;Hélène Ribault.;Karim Fizazi.; .
来源: Lancet. 2024年404卷10467期2065-2076页
The 2 × 2 PEACE-1 study showed that combining androgen-deprivation therapy with docetaxel and abiraterone improved overall and radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer. We aimed to examine the efficacy and safety of adding radiotherapy in this population.
58. Balloon guide catheters for endovascular thrombectomy in patients with acute ischaemic stroke due to large-vessel occlusion in China (PROTECT-MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
作者: Jianmin Liu.;Yu Zhou.;Lei Zhang.;Zifu Li.;Wenhuo Chen.;Yueqi Zhu.;Xiaoxi Yao.;Liyong Zhang.;Shen Liu.;Ya Peng.;Ming Wei.;Quanbin Zhang.;Hansheng Shu.;Shouchun Wang.;Wenhua Liu.;Shu Wan.;Tong Li.;Yibin Fang.;Hongxing Han.;Guang Zhang.;Li'an Huang.;Feng Wang.;Guangsen Cheng.;Lianbo Gao.;Hongchao Shi.;Jintao Han.;Yun Luo.;Shuai Li.;Chuwei Cai.;Rong Yin.;Zhenglong Jin.;Chengwei Shao.;Bing Tian.;Yongxin Zhang.;Qiang Li.;Yingying Zhang.;Ping Zhang.;Binben Li.;Pengfei Xing.;Hongjian Shen.;Xuan Zhu.;Xiaoxi Zhang.;Weilong Hua.;Fang Shen.;Meihua Huyan.;Rundong Chen.;Qiao Zuo.;Qiang Li.;Qinghai Huang.;Yi Xu.;Benqiang Deng.;Rui Zhao.;Mayank Goyal.;Yongwei Zhang.;Pengfei Yang.; .
来源: Lancet. 2024年404卷10468期2165-2174页
The effectiveness of using a balloon guide catheter during endovascular thrombectomy in patients with acute ischaemic stroke due to large vessel occlusion of the anterior circulation remains uncertain. We aimed to assess the effectiveness and safety of using a balloon guide catheter during endovascular thrombectomy, compared with using a conventional guide catheter, in this patient population.
59. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.
作者: Jeremy S Abramson.;Matthew Ku.;Mark Hertzberg.;Hui-Qiang Huang.;Christopher P Fox.;Huilai Zhang.;Dok Hyun Yoon.;Won-Seog Kim.;Haifaa Abdulhaq.;William Townsend.;Charles Herbaux.;Jan M Zaucha.;Qing-Yuan Zhang.;Hung Chang.;Yanyan Liu.;Chan Yoon Cheah.;Herve Ghesquieres.;Stephen Simko.;Victor Orellana-Noia.;Richard Ta.;James Relf.;Mark Dixon.;Martine Kallemeijn.;Estefania Mulvihill.;Huang Huang.;Linda Lundberg.;Gareth P Gregory.
来源: Lancet. 2024年404卷10466期1940-1954页
Glofitamab monotherapy induces durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more previous therapies, but has not previously been assessed as a second-line therapy. We investigated the efficacy and safety of glofitamab plus gemcitabine-oxaliplatin (Glofit-GemOx) versus rituximab (R)-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma.
60. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.
作者: Yvonne M Mowery.;Karla V Ballman.;Angela M Hong.;Scott M Schuetze.;Andrew J Wagner.;Varun Monga.;Rachel S Heise.;Steven Attia.;Edwin Choy.;Melissa A Burgess.;Susie Bae.;David I Pryor.;Brian A Van Tine.;Gabriel Tinoco.;Bartosz Chmielowski.;Carolyn Freeman.;Alessandro Gronchi.;Christian F Meyer.;Mark A Dickson.;Lee Hartner.;Lara E Davis.;Benjamin C Powers.;Everett J Moding.;Kent J Weinhold.;Matt van de Rijn.;Brian E Brigman.;Richard F Riedel.;David G Kirsch.
来源: Lancet. 2024年404卷10467期2053-2064页
Approximately half of patients with localised, high-risk soft tissue sarcoma of the extremity develop metastases. We aimed to assess whether the addition of pembrolizumab to preoperative radiotherapy and surgery would improve disease-free survival.
|